Bonnie Gail Franklin passed on today at age 69 due to pancreatic cancer. To those of a certain age (this author included) Ms. Franklin will always be associated with Ann Romano, her role as the divorced mother of two in the sitcom “One Day at a Time” on CBS from December 1995 until 1984. This was one of Norman Lear’s series that attempted to portray a more real America to TV viewers, and Bonnie Franklin admirably filled that role.
She played the Ann Romano role as complex with the uncertainties as well as compensations of a single mom raising her girls in a changing world. The daughters were played by Mackenzie Phillips (daughter of founders of the Mammas and Pappas pop singing group) and by Valerie Bertinelli (who later married rock star Eddie Van Halen – and has continued on as a star in her own right). Pat Harrington played with humor the character of the building supervisor, Dwayne Schneider.
Bonnie Franklin was a California gorl. She was born in Santa Monica and attended Beverly Hill High School. Later she went to Smith College and eventually back to UCLA. Her first role as an actor was at age nine in the Colgate Comedy Hour. She acted in television, movies and theatre including Broadway productions. She was nominated for Emmy awards, a Tony, and for the Golden Globes.
In September of 3012 Bonnie Franklin was diagnosed with pancreatic cancer. She died at her home in Los Angles earlier today.
May Bonnie Gail Franklin rest in peace. And may her friends and family accept our deepest condolences. She was a lovely and talented actress.
Dale O’Brien, MD
Overshadowed perhaps by the positive results of Von Hoff and colleagues’ research on Abraxane plus gemcitabine for advanced pancreatic cancer, an interesting study on the treatment of LOCALLY ADVANCED pancreatic cancer was presented at the recent ASCO Gastrointestinal Cancers Symposium in San Francisco late January.
In locally advanced cancer of the pancreas the treatment is generally chemoradiotherapy, meaning radiation therapy plus chemotherapy – the chemo often being the drug-agent gemcitabine.
Mukherjee of Oxford University and British colleagues presented a meeting abstract of the results of their unyet unpublished work on a Phase II clinical trial that showed a modest survival advantage by using capecitabine (Xeloda) as compared to gemcitabine as the chemo component of chemoradiation for locally advanced pancreatic cancer.
Capecitabine is a pro-drug that is converted into 5-FU by the body. It is also given orally. The study results by Mukherjee indicated that the regimen that included capecitabine offered less side-effects as compared to that of the gemcitabine regimen.
It will be interesting to see this work in a peer-reviewed medical journal, and to see if the results will be replicated over time.
Dale O’Brien, MD
BRCA1 and BRCA2 genes are important in the repair and upkeep of DNA. Mutations in these genes confer a strong tendency to not only more widely known breast cancer, but to other kinds of cancers as well – including contributing to some amount of pancreatic cancer.
Now, researchers from the Women’s College Research Institute, Familial Breast Cancer Research in Toronto, Canada have published a study in the British Journal of Cancer which has attempted to quantify this increased risk.
Huzarski and colleagues followed women with either an identified BRCA1 or a BRCA2 mutation, and reviewed pedigrees. They found that the risk of either mutation increased the risk of acquiring pancreatic cancer to about double of that of the risk of the general population.
Dale O’Brien, MD